Damien Vansteene
Integrated Oncology (United States)(US)Institut de Cancérologie de l'Ouest(FR)
Publications by Year
Research Areas
Nutrition and Health in Aging, Cancer Immunotherapy and Biomarkers, Frailty in Older Adults, Head and Neck Cancer Studies, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial(2021)218 cited
- → TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).(2019)82 cited
- → NutriCancer: A French observational multicentre cross-sectional study of malnutrition in elderly patients with cancer(2017)61 cited
- → Nutrition and physical activity: French intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC, SFP-APA, SFNCM, AFSOS)(2020)28 cited
- → Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial(2021)27 cited
- → Is sarcopenia a missed factor in the management of patients with metastatic breast cancer?(2021)25 cited
- → TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).(2020)24 cited
- → Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma(2021)24 cited
- → Prognostic factors of colorectal cancer patients with brain metastases(2021)20 cited
- → Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.(2023)13 cited